Induction of plasminogen activator inhibitor by products released from platelets
- PMID: 2401077
- DOI: 10.1161/01.cir.82.4.1485
Induction of plasminogen activator inhibitor by products released from platelets
Abstract
Activation of platelets and augmentation of plasma plasminogen activator inhibitor (PAI) type I activity accompany acute myocardial infarction. To determine whether the two may be related, platelet compounds including epidermal growth factor and transforming growth factor beta as well as platelet lysates were studied in rabbits in vivo. After intravenous infusion of epidermal growth factor (1 and 5 micrograms/kg), plasma PAI activity increased sevenfold and 20-fold, peaking at 2 hours. After infusions of transforming growth factor beta (0.2 and 0.5 microgram/kg), plasma PAI activity increased sevenfold and 12-fold but peaked more slowly (at 5 hours). After infusion of platelet lysates (lysates from 2.8 and 5.6 X 10(8) platelets/kg), the increase was 19-fold and 35-fold, with a peak at 4 hours. Platelet lysates induced a pronounced increase of plasma PAI type 1 messenger RNA (Northern blots) in aorta, liver, and myocardium. Anti-transforming growth factor beta neutralizing antibody markedly attenuated the plasma PAI increase. Concentrations in plasma of fibrinogen and alpha 2-antiplasmin were virtually unaffected under all conditions. Thus, platelet-associated growth factors and platelet lysates, shown previously to increase plasma PAI type 1 messenger RNA expression and protein production in cultured hepatocytes and vascular endothelial cells in vitro, augment plasma PAI in vivo as well. Accordingly, activation of platelets and release of platelet-associated growth factors appear to contribute to the increased plasma PAI seen after myocardial infarction.
Similar articles
-
Mediators of induction of augmented expression of plasminogen activator inhibitor type-1 in Hep G2 cells by platelets.Thromb Haemost. 1991 Aug 1;66(2):239-45. Thromb Haemost. 1991. PMID: 1663280
-
Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis.Circulation. 1991 Feb;83(2):645-51. doi: 10.1161/01.cir.83.2.645. Circulation. 1991. PMID: 1991382
-
Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1.Circulation. 1992 May;85(5):1888-93. doi: 10.1161/01.cir.85.5.1888. Circulation. 1992. PMID: 1572044
-
Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications.Am J Cardiol. 1989 Jun 15;63(20):1505-11. doi: 10.1016/0002-9149(89)90016-7. Am J Cardiol. 1989. PMID: 2499173
-
Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo.Circulation. 1992 Dec;86(6):2000-10. doi: 10.1161/01.cir.86.6.2000. Circulation. 1992. PMID: 1451272
Cited by
-
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice.Mol Med. 1997 Jan;3(1):37-48. Mol Med. 1997. PMID: 9132278 Free PMC article.
-
Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy.Am J Pathol. 1993 Sep;143(3):753-62. Am J Pathol. 1993. PMID: 8362974 Free PMC article.
-
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.J Clin Invest. 1991 Oct;88(4):1346-53. doi: 10.1172/JCI115440. J Clin Invest. 1991. PMID: 1918385 Free PMC article.
-
Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.J Thromb Thrombolysis. 1995;2(2):107-112. doi: 10.1007/BF01064377. J Thromb Thrombolysis. 1995. PMID: 10608012
-
Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.Clin Rheumatol. 1997 May;16(3):254-60. doi: 10.1007/BF02238960. Clin Rheumatol. 1997. PMID: 9184262 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources